Wegovy and Mounjaro both rely on a self-administered pen, taken once a week
Concerning reactions that warrant medical review: Progressive swelling increasing size of a lump or swelling over 2448 hours Persistent redness redness that spreads beyond the immediate injection site or intensifies rather than fading Warmth and pain the injection site feels hot to touch and becomes increasingly painful, suggesting possible infection (cellulitis) Systemic symptoms fever, chills, or feeling generally unwell following an injection Allergic-type reactions hives, itching, or rash developing at or beyond the injection site Severe, persistent abdominal pain especially if radiating to the back, with or without vomiting (possible pancreatitis) Jaundice yellowing of the skin or eyes, which could indicate gallbladder problems (a known risk with Saxenda) It is important to note that there is no official link between Saxenda and increased bleeding disorders or coagulopathy
2.4 mg is the highest maintenance dose evaluated [1] [3]
Its involved in regulating your appetite, blood sugar, and digestion
While it showed promise in preclinical studies and limited human trials, it was never advanced to late-stage clinical development or FDA approval
Neoplasia 10 , 12951302 (2008)
